G protein-coupled receptors are differentially regulated in the right ventricle in pulmonary hypertension, contributing to adverse remodeling and serving as potential therapeutic targets.
Because the right ventricle responds differently to pressure overload and pharmacological agents compared to the left ventricle, GPCR-targeted therapies must be specifically evaluated for their direct effects on right ventricular remodeling in pulmonary hypertension.
Pressure overload of the right ventricle (RV) in pulmonary arterial hypertension (PAH) leads to RV remodeling and failure, an important determinant of outcome in patients with PAH. Several G protein-coupled receptors (GPCRs) are differentially regulated in the RV myocardium, contributing to the pathogenesis of RV adverse remodeling and dysfunction. Many pharmacological agents that target GPCRs have been demonstrated to result in beneficial effects on left ventricular (LV) failure, such as beta-adrenergic receptor and angiotensin receptor antagonists. However, the role of such drugs on RV remodeling and performance is not known at this time. Moreover, many of these same receptors are also expressed in the pulmonary vasculature, which could result in complex effects in PAH. This manuscript reviews the role of GPCRs in the RV remodeling and dysfunction and discusses activating and blocking GPCR signaling to potentially attenuate remodeling while promoting improvements of RV function in PAH.
Viswanathan et al. (Mon,) conducted a review in Pulmonary Hypertension. GPCR targeted therapies was evaluated. G protein-coupled receptors are differentially regulated in the right ventricle in pulmonary hypertension, contributing to adverse remodeling and serving as potential therapeutic targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: